Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
Therapy Area
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Aktis Oncology kicks 2026 IPO cycle off with $210m target
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Biogen’s Tysabri to be used on England’s NHS for highly active MS
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
Genmab shelves Phase III lung cancer candidate
